CellectCell Making Progress Toward Finish Line

Primary tabs

CellectCell, a company spawned in labs at the Petit Institute for Bioengineering and Bioscience, is moving steadily toward commercial viability.

“We have recently begun pilot production for our initial product, the CellectCell MicroCassette™, and will have beta units in the next few months,” says Rebecca Marshall, president and CEO of CellectCell. “We are very excited about the progress we have made toward commercializing this novel, label-free cell isolation technology.”

The company is the brainchild of co-founders Andrés García and Todd McDevitt, who have deep roots in the Petit Institute and the Georgia Institute of Technology.

García, the Rae S. and Frank H. Neely Chair and Regents’ Professor in the Woodruff School of Mechanical Engineering, is a longtime faculty researcher at the Petit Institute. McDevitt, former Petit Institute researcher and director of the Stem Cell Engineering Center at Georgia Tech, is now a senior investigator at the Gladstone Institutes and professor in the Department of Bioengineering & Therapeutic Sciences at the University of California-San Francisco.

The company is built on technology and methods developed by García, McDevitt and fellow researchers at Georgia Tech: Ankur Singh and Shalu Suri (researchers at Cornell University, and former postdoctoral fellows at Georgia Tech) and Hang Lu (Petit Institute faculty researcher, professor in the School of Chemical and Biomolecular Engineering).

In December 2014, Atlanta-based Medtown Ventures, LLC (a firm that specializes in growing promising life science companies) entered into an exclusive license agreement with the Georgia Tech Research Corporation to form CellectCell with co-founders García and McDevitt to commercialize their innovative adhesive-signature based stem cell selection and isolation technology.

The CellectCell MicroCassette™ leverages the adhesive-signature based methodology to rapidly isolate specific populations of cells with greater than 95 percent purity and yield. Medtown’s managing director, Chris Fair, calls it, “game-changing technology for both research based activities as well as product development.”


Clutch Assist from GRA

Last fall, the Georgia Research Alliance (through the GRA Ventures Program) stepped up with critical Phase II funding to support CellectCell’s efforts toward developing a disposable cell isolation cassette for academic and commercial research.

Marshall, a Medtown director, says the collaboration with GRA will help transform the technology into products that allow researchers and manufacturing companies to select for specific cell types with higher sensitivity and specificity than what is currently available. Because the technology is based on the inherent properties of cells, and is label-free, the process does not adversely affect cell viability or phenotype.

“The technology exploits differences in the adhesive force of different cell types to purify or isolate specific populations from heterogeneous or mixed cultures,” says García, who has used the technology to purify stem cells and differentiated cells, as well different cancer cell types from biopsied tumors.

“We expect that many researchers will find this technology very useful and effective in isolating target cell populations faster, cheaper, and better than current methods,” he adds.

In order to make that happen, it takes a team. Much like the multidisciplinary researchers at the Petit Institute approach common problems from different, interrelated angles, it takes a number of different pieces and moving parts to spin a company out of lab discovery. Basically, CellectCell couldn’t exist without the contribution of something like Medtown.

“There are many important considerations in commercialization and translation that I as a researcher did not appreciate or understand,” says García. “Working with Rebecca and Medtown has allowed this to move forward. They have been invaluable.”

For the past year and a half, Marshall has been running point for CellectCell, as its appointed executive leader and at the moment the only full-time employee.

“My job is basically to keep everyone driving toward the finish line,” she says. “Keeping everyone focused so we’re not chasing down more than we can handle. With platform technology like this, there might be three million things we can see the product being used for, but if we try to focus on all of that at the same time, we won’t get there.”

So, the immediate big challenge, says García, “is transitioning from a lab-scale technology used by researchers that developed it and are very familiar with all the ins and outs to an easy-to-manufacture technology to be broadly used by different researchers that have no prior experience with this platform.”

Another primary role for Marshall, of course, is fundraising. The GRA support couldn’t have come at a better time, she says. And with functional prototypes that work now, and beta units on the market soon, CellectCell will have better opportunities to raise money, she says.

With pilot production underway, commercialization is right around the corner, and the goal is to have the MicroCassette™ widely available in the first half of 2017.

“Our vision,” says Marshall, “is to improve the ease and precision of cell isolation for researchers world-wide, by providing them with a versatile research tool that can be used for every single cell isolation, something on the shelf that becomes as commonplace to researchers as a pipette or culture dish.”




Medtown Ventures

García Lab

McDevitt Lab



Jerry Grillo
Communications Officer II
Parker H. Petit Institute for
Bioengineering and Bioscience


  • Workflow Status: Published
  • Created By: Jerry Grillo
  • Created: 11/03/2016
  • Modified By: Jerry Grillo
  • Modified: 11/03/2016


No categories were selected.

Target Audience